The Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus (LGA-IRT) supports projects that advance the development of next-generation engineered cell therapies with a clear and direct relevance to people with lupus (up to $300,000 over two years for pre-clinical studies, including discovery and translational projects, or up to $600,000 over two years for ancillary studies to ongoing or completed engineered cell therapy clinical trials for lupus).
2026 Funded Grants
-
Mechanisms for B cell tolerance following deep B cell depletion
Anne Davidson, MBBS
The Feinstein Institutes for Medical Research
-
Immune reprogramming in Systemic Lupus Erythematosus following CD19 CAR T cell treatment
Panagiotis Garantziotis, MD, PhD
Uniklinikum Erlangen
-
Impact of CD19-targeted CAR T cell therapy on B cell tolerance in SLE
Eric Meffre, PhD
Stanford University